Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3 Meeting Abstract
| Authors: | Milowsky, M. I.; Dittrich, C.; Martinez, I. D.; Jagdev, S.; Millard, F. E.; Sweeney, C.; Bajorin, D. F.; Cerbone, L.; Dunn, R. M.; Sen, P.; Shi, M.; Kay, A. C. M.; Squires, M.; Sternberg, C. N. |
| Abstract Title: | Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3 |
| Meeting Title: | 2013 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2013 Feb 14-16 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-02-20 |
| Language: | English |
| ACCESSION: | WOS:000333679600255 |
| DOI: | 10.1200/jco.2013.31.6_suppl.255 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 255 -- Source: Wos |
